Clinical Trial Update: Dose Escalation of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck or Esophagus [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of the antibody-drug conjugate Bivatuzumab mertansine in patients with advanced squamous cell carcinoma of the head and neck or es…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma of the Esophagus
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Bivatuzumab mertansine (bivatuzumab mertansine)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Squamous Cell | Phase 1 | Status: TERMINATED